Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Molecular Devices

Molecular Devices provides innovative bioanalytical solutions for protein and cell biology in life science research, ... read more Featured Products: More products

Download Mobile App




Immunomarker Found for Recurring HPV-Linked Oropharyngeal Cancers

By LabMedica International staff writers
Posted on 24 Feb 2016
Human papilloma virus (HPV) infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers (OPC) linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk.

People with HPV-positive tumors of the throat, base of the tongue and tonsils have higher overall survival rates compared to people with similar tumors not caused by HPV, but studies show that more than 25% of HPV-positive cancers recur, usually within the first two years after treatment.

Scientists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) designed a retrospective study to determine whether HPV16 antibody titers change after treatment. More...
Participants with HPV-OPC and two or greater serology specimens available were eligible. HPV16 tumor status was obtained from previously reported data which included real time polymerase chain reaction (qPCR) for HPV16 genomic DNA (≥0.1 copy per genome) and high risk HPV in situ hybridization. A subset analysis was restricted to participants with clinically available HPV16-positive in situ hybridization tumor status.

Antibodies to HPV16 E1, E2, E6, and E7 were measured by enzyme-linked immunosorbent assay (ELISA) using the glutathione S-transferase (GST) capture method with some modifications. The ELISA optical density (OD) was measured at 405 nm, with a reference wavelength of 490 nm, in an automated microtiter plate reader (Molecular Devices; Sunnyvale, CA, USA). The mean OD in wells with GST alone was subtracted from the mean OD in wells with the GST-HPV protein to give an antigen-specific OD value.

The team analyzed blood serum samples of 60 patients with HPV-positive oropharyngeal cancer and a median age of 56, mostly Caucasian men. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 and E7. Among the 60 patients, they identified six cases of recurring cancer within an average of 4.4 years of follow-up after treatment.

Carole Fakhry, MD, MPH, the lead author of the study, said, “There are currently no reliable tests available to detect early recurrence, so we hope to find a biological marker that could help identify those most at risk. Potentially, a low-risk patient may need less stringent surveillance while a high-risk patient may require more intense imaging.” The study was published online on December 31, 2015, in the journal Cancer Prevention Research.

Related Links:

Johns Hopkins University School of Medicine 
Molecular Devices 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.